Cutia Therapeutics Reports 30.6% Drop in Revenue to RMB66.3 Million and 19.1% Narrower Net Loss for Six Months Ended June 2025
Reuters
Sep 26
Cutia <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports 30.6% Drop in Revenue to RMB66.3 Million and 19.1% Narrower Net Loss for Six Months Ended June 2025
Cutia Therapeutics reported its results for the six months ended 30 June 2025, with revenue decreasing 30.6% year-on-year to RMB66.3 million, compared to RMB95.6 million for the same period in 2024. The company attributed the decline primarily to the termination of its agency cooperation with US skincare brand Phyto-C, influenced by macroeconomic policies and international environmental factors. Resources were reallocated to support commercialization preparations for newly approved products, including CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam), which the company projects to have greater market potential and higher return on investment. Net loss for the period narrowed by approximately 19.1% from a loss of RMB200.9 million for the six months ended 30 June 2024. Cutia Therapeutics emphasized its continued commitment to commercializing its new dermatology treatment products in the second half of 2025. The company reported no significant events affecting the group after the reporting period and up to the date of the report.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cutia Therapeutics published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.